FDA Approves New MCL Treatment: BTK Inhibitor Strategy
News from News Directory 3: the FDA has approved acalabrutinib, a new Bruton tyrosine kinase (BTK) inhibitor strategy, for adults with previously untreated mantle cell lymphoma (MCL) unable to undergo stem cell transplant. This approval, based on the phase 3 ECHO trial, demonstrates acalabrutinib’s efficacy, significantly improving progression-free survival. Oncology pharmacists are crucial in managing potential side effects. Understand the critical role of this new treatment approach and its implications, including a look at the benefits and managing adverse events. Discover the improvements in response rates through the use of BTK inhibitors and its role in mantle cell lymphoma treatment effectiveness. Explore the evolving landscape of MCL therapies and what this approval means for patient care.Discover what’s next …
Acalabrutinib Okayed for Mantle cell Lymphoma Treatment
The Food and Drug Governance (FDA) approved acalabrutinib (Calquence, AstraZeneca) in January 2025 for use with bendamustine and rituximab to treat adult patients with previously untreated mantle cell lymphoma (MCL).This combination is specifically for individuals not eligible for autologous hematopoietic stem cell transplantation (HSCT).
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, works by disrupting B-cell receptor signaling pathways that are vital for B-cell proliferation and survival. By selectively inhibiting BTK, acalabrutinib curtails the activation of NF-κB, PI3K, and MAPK pathways, which encourages apoptosis and impedes the proliferation of malignant B cells. Compared to earlier BTK inhibitors like ibrutinib, acalabrutinib is more selective, leading to fewer off-target effects and better tolerability, according to clinical data.
The approval was based on findings from the phase 3 ECHO trial, which were presented at the 2024 European Hematology Association hybrid Congress. The study involved 598 patients, aged 65 or older, with previously untreated MCL. Participants were randomly assigned to receive either 100 mg of acalabrutinib or a placebo twice daily, along with six cycles of bendamustine and rituximab. Responding patients then received maintenance rituximab for two years. Those in the placebo group were allowed to switch to acalabrutinib if their disease progressed.
After a median follow-up of 45 months, the overall response rate (ORR) in the acalabrutinib group was 91%, compared to 88% in the placebo group. Complete response rates were also higher in the acalabrutinib arm, at 66.6% versus 53.5%. The trial’s primary endpoint, progression-free survival (PFS), showed a significant advancement with acalabrutinib. The median PFS was 66.4 months, compared to 49.6 months in the placebo group (HR, 0.64; 95% CI, 0.48-0.84; P = .0017). The median overall survival was not reached in either group.
adverse events (AEs) were closely monitored in the trial. Grade 3 or higher treatment-emergent AEs (TEAEs) occurred in 88.9% of the acalabrutinib group and 88.2% of the placebo group.Serious TEAEs were reported in 69% and 62% of patients, respectively. Treatment discontinuation due to TEAEs occurred in 42.8% of the acalabrutinib group and 31% of the placebo group.
Common AEs included infections (78.1% in the acalabrutinib group vs 71% in the placebo group), hypertension (12.1% vs 15.8%, respectively), atrial fibrillation (6.1% vs 4.4%, respectively), second primary malignancies (9.8% vs 10.8%,respectively),and major bleeding events (2.4% vs 5.4%, respectively).
Oncology pharmacists are essential in managing patients on acalabrutinib. Their responsibilities include implementing supportive care strategies to manage treatment-related AEs, such as using corticosteroids for lymphadenopathy and inflammatory responses, loperamide for diarrhea, topical treatments for rash, and antihypertensive medications for blood pressure control. Acetaminophen can be used to alleviate arthralgia, myalgia, and headaches.
Pharmacists also monitor for cytopenias, arrhythmias, and bleeding, especially in patients taking antithrombotic drugs. Although there are no formal contraindications, acalabrutinib may need to be held for three to seven days before and after surgery to minimize bleeding risks. Hepatotoxicity and drug-induced liver injury are also risks that require monitoring.
Additionally, pharmacists perform drug interaction checks, counsel patients on adherence and administration, coordinate supportive care, and facilitate financial navigation and medication access.
What’s next
The approval of acalabrutinib in combination with bendamustine and rituximab provides a new option for previously untreated MCL patients who cannot undergo intensive therapy, marking a significant advancement in MCL treatment.